Societe De Therapeutique Marocaine Sa (Morocco)

The Company is a Morocco-based company specialized in production and marketing of drugs. The company provides drugs in the forms of tablets, capsules, syrups, ampoules, creams and ointments, as well as powders and suspensions for injections, among others. It exports the substantial share of its output to Europe, North and sub-Saharan Africa, among others, and it is also engaged in the manufacture of drugs under license and the importation of dental products. The Company operates a subsidiary, West Afric Pharma, based in Senegal.
The Company was founded on Jaunary 26, 1976.
The Company was listed in Casablanca Stock Exchange on February 21, 2005.
History
1976 :Creation of Sothema.
1981:Inauguration of the Bouskoura site.
1982:Beginning of the production of insulin and injectable solutions.
1990:Beginning of shaping.
1998:Launch of the penicillin unit.
2000:Launch of the cephalosporins unit.
2004:Laying of the foundation stone of the West Afric subsidiary
Pharma in Senegal.
2005:Initial in stockexchange
2009:Launch of the sterile blocks unit
2010:Acquisition of the Novartis Morocco site.
2016:Manufacture of the first anti-cancer products
from biotechnology in Morocco.
2017:Patent resulting from the first basic research in the field
100 Moroccan antibiotic therapy with the Faculty of Medicine of
Fes. A project sanctioned by the European Inventor AWARD and a
decoration of His Majesty the King, may God assist him.
2019:Inauguration of the biosimialires unit, of the second production site for serums in flexible pouches and of a biomass boiler
for the production of clean energy.
2020: this is first publication of consolidated accounts of the SOTHEMA Group.
-Realization on behalf of the Ministry of Health and the giant
Chinese Sinopharm, of the first clinical trial on a candidate anti-Covid-19 vaccine on the scale of Africa.
2021:Provision of Sothema s industrial facilities in
view of manufacturing on behalf of the Ministry of Health of
first batches of anti-covid 19 vaccines.
2022: The Company conforte sa dynamique de croissance grace a son portefeuille de produits differenceies et sa strategy d expansion a l international. Cette
approche combinee est l'essor de la vision du groupe, portee par la diversification des activites avec des perspectives prommetteuses de croissance organique
et externe a court et moyen terme nous avons mene notre croissance avec une gestion disciplineee des expenses et l'etenude de nos efforts de commercialization sur le
African continent, Middle-East and Europe. Once again, le marche emergent du Senegal has strongly contributed to our performances accomplished by the subsidiary
West Afric Pharma qui a atteint d excellentes realizations.
2023:Inauguration of Axess Pharma.